RC
RLMD icon

RBF Capital’s Relmada Therapeutics RLMD Stock Holding History

RBF Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-120,000
Closed -$835K – 526
2026
Q1 		$835K Sell
120,000
-20,000
-14% -$94.6K 0.04% 313
2025
Q4 		$676K Sell
140,000
-23,261
-14% -$77.9K 0.03% 359
2025
Q3 		$328K Hold
163,261
– – 0.01% 453
2025
Q2 		$98K Hold
163,261
– – ﹤0.01% 575
2025
Q1 		$44.1K Hold
163,261
– – ﹤0.01% 566
2024
Q4 		$84.9K Sell
163,261
-2,213
-1% -$5.4K ﹤0.01% 531
2024
Q3 		$536K Hold
165,474
– – 0.03% 403
2024
Q2 		$496K Hold
165,474
– – 0.03% 380
2024
Q1 		$769K Hold
165,474
– – 0.04% 326
2023
Q4 		$685K Sell
165,474
-28,600
-15% -$84.7K 0.04% 327
2023
Q3 		$582K Hold
194,074
– – 0.04% 333
2023
Q2 		$477K Buy
+194,074
New +$537K 0.03% 369

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RBF Capital's RLMD Position: Q2 2026 in Review

RBF Capital sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 120,000 shares — an estimated $835K sold.

RBF Capital first reported a position in RLMD in Q2 2023 and held it in 12 quarters. The position peaked at $835K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • RBF Capital reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • RBF Capital sold 120,000 Relmada Therapeutics shares in Q2 2026, an estimated $835K.
  • RBF Capital first reported a position in Relmada Therapeutics in Q2 2023 and held it in 12 quarters.
  • RBF Capital's Relmada Therapeutics position peaked at $835K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on RBF Capital's 13F filing for Q2 2026, filed 14 Aug 2026.